Search

Displaying results 5921 - 5930 of 10000 in total
  1. Pathway

    Cardiolipin Biosynthesis CL(i-14:0/i-21:0/i-22:0/i-22:0)

    smpdb.ca/view/SMP0486778
    Metabolic

    Cardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  2. Pathway

    Cardiolipin Biosynthesis CL(i-14:0/i-21:0/i-24:0/i-24:0)

    smpdb.ca/view/SMP0486815
    Metabolic

    Cardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  3. Pathway

    Cardiolipin Biosynthesis CL(i-15:0/i-21:0/i-21:0/i-21:0)

    smpdb.ca/view/SMP0487036
    Metabolic

    Cardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  4. Pathway

    Cardiolipin Biosynthesis CL(i-15:0/i-22:0/i-22:0/i-24:0)

    smpdb.ca/view/SMP0491912
    Metabolic

    Cardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  5. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [L48041] While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy

    Synonyms: IMMUNOGLOBULIN G4 (HUMAN-MOUSE MONOCLONAL AN100226 4-CHAIN ANTI-HUMAN INTEGRIN 4), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL AN100226 LIGHT CHAIN, DIMER, IMMUNOGLOBULIN G4 (HUMAN-MOUSE MONOCLONAL AN100226 4-CHAIN ANTI-HUMAN INTEGRIN 4), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL AN100226 LIGHT CHAIN, DIMERProducts: TYSABRI®, TYSABRI® SUBCUTÁNEO 150MG/ML
  6. Drug

    Ephedrine

    go.drugbank.com/drugs/DB01364
    ApprovedInvestigational

    [L12972] Ephedrine and [phenylephrine] are still used to treat hypotension, but their use in other indications has decreased due to the development of more selective adrenergic agonists. … It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepinephrine from sympathetic neurons, inhibiting norepinephrine reuptake and displacing more norepinephrine

    Mixtures: NEO NAPACIN, NEO YEKASTHMASynonyms: L-erythro-2-(Methylamino)-1-phenylpropan-1-ol, (1R,2S)-1-Phenyl-1-hydroxy-2-methylaminopropane
  7. Drug

    Glimepiride

    go.drugbank.com/drugs/DB00222
    ApprovedInvestigational

    [A177709] Glimepiride works by stimulating the secretion of insulin granules from pancreatic islet beta cells by blocking ATP-sensitive potassium channels (K<SUB>ATP</SUB> channels) and causing depolarization … The main effect of SUs is thought to be effective when residual pancreatic β-cells are present,[A177715] as they work by stimulating the release of insulin from the pancreatic beta cells and they are also

    Mixtures: AMARYL®M 1 MG/ 500 MG, AMARYL®M 4 MG/ 1000 MGCategories: Drugs Used in Diabetes, Cytochrome P-450 Substrates
  8. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    It was originally approved by the U.S. … On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].

    Categories: CHOP-R chemotherapy regimenProducts: TRUXİMA 500 MG/50 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, MABTHERA 100 MG/10 ML IV INFUZYON İÇİN KONSANTRE ÇÖZELTİ İÇEREN FLAKON, 2 ADET
  9. Drug

    Chymopapain

    go.drugbank.com/drugs/DB06752
    ApprovedWithdrawn

    [L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.

    Products: Chymodiactin Injection - 4 Nkat Units/2ml
  10. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high